Navigation Links
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Date:12/23/2011

MOUNTAIN VIEW, Calif., Dec. 23, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on October 17, 2011 seeking approval to market Qnexa in the United States. The FDA accepted the NDA for review on November 3, 2011. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012. 

About QnexaQnexa [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking Qnexa have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators.  VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010.  We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012.  Qnexa is also in phase 2 clinical development for the treatment of type
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... - The Lancet Launches a New Initiative ... an Archive of Science for Health and Human,Development, ... the launch of a new, editorially,independent global health ... ., The network will search and archive ...
... 7, 2008 Varian, Inc.,(NasdaqGS: VARI) announced today ... owned company based in Abingdon, U.K. Oxford Diffraction,is ... used by,scientists in pharmaceutical research and other research ... and large molecules such as,proteins., For crystalline ...
... Schoolchildren who required surgery as infants for congenital ... having problems with inattention and hyperactivity, and often ... at risk for academic and behavior problems, and ... provide them with ongoing follow-up and neurodevelopmental screening, ...
... 2008 News stories about an allegedly harmful link ... onset of autism had little effect on whether U.S. ... immunization records and news stories. Parents decisions were more ... researchers said. , Researchers from The Children,s Hospital of ...
... Ingrid Bells turn at bat. She steps up to the plate, ... and connects with the ball. , Foul ball! Everyone cheers for ... a field, and theres no real bat or ball to be ... her occupational therapy. She is among 30 Parkinsons disease patients participating ...
... data of 221 men and women found that the ... death showed evidence of small, cumulative blood vessel damage ... Thomas Montine and colleagues analyzed the brain tissue of ... study, wherein 3,400 adult participants (65+) in the Seattle ...
Cached Medicine News:Health News:The Lancet Global Health Network 2Health News:The Lancet Global Health Network 3Health News:The Lancet Global Health Network 4Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 2Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 3Health News:For children with heart disease, a risk of attention and behavior problems 2Health News:Parents follow pediatrician advice on administering MMR vaccinations 2Health News:Parents follow pediatrician advice on administering MMR vaccinations 3Health News:Occupational therapists use Wii for Parkinson's study 2
7 1/2" Bayonet Monopolar Forceps, Ins., Serrated...
Extended blade - 25/box....
... and workmanship are the hallmark of these ... in mind. The top (incident) circular 9W ... shadows while remaining cool to the touch. ... with 10x to 44x zoom magnification or ...
... Nikon's evanescent wave imaging system utilizes ... molecules in the thin section in ... structure". This unique design permits simultaneous ... illumination systems, with no restriction on ...
Medicine Products: